Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, variant U1 small nuclear 34 (RNVU1-34) is an annotated noncoding RNA gene summarized as a variant form of U1 small nuclear RNA. It is classified as a pseudogene or active variant possibly involved in pre-mRNA 5′-splice site recognition and U1 snRNP formation, based mainly on predictive annotation rather than experimental data. The canonical U1 snRNA is critical for spliceosome assembly and pre-mRNA splicing, and some variant U1 snRNAs show differential expression and functional impacts in model systems. However, for RNVU1-34 specifically, there is no evidence for a unique biological role, disease association, or targeting by drugs in the literature. Many variant U1 snRNAs expressed from pseudogenes are packaged into RNP complexes and may regulate gene expression at the level of pre-mRNA processing, but RNVU1-34 remains uncharacterized beyond bioinformatic prediction.
None (No drugs or compounds are known to target this molecule directly; mechanisms described in literature pertain to U1 snRNP assembly and function, not pharmacological modulation)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, variant U1 small nuclear 34 (RNVU1-34).